Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorAalborg University Hospital
About this trial
The DanAblate-HF trial will investigate whether early catheter ablation treatment for atrial fibrillation in patients with heart failure is superior to standard treatment.
Eligibility criteria
Qualifiers
HF patients with AF within the past 12 months
Clinically assessed Heart Failure with Reduced Ejection Fraction (HFrEF)
An indication for initiation or ongoing guideline directed medical therapy for HFrEF, according to current Heart Failure guidelines
LVEF < 50% at any point during the past 12 months
Disqualifiers
Life-expectancy < 1 year
BMI > 40
Contraindications or unacceptable side effects to rate limiting drugs AND amiodarone
LA size (indexed for BSA) > 60 ml/m2 (volume) on echo within the last year
Trial design
Treatments tested in this trial
- Catheter ablation
Treatment groups
1,616 Participants
are divided into 2 treatment groupsSponsors and collaborators
Aalborg University Hospital
Lead sponsor
Rigshospitalet, Denmark
Collaborator
Odense University Hospital
Collaborator
Aarhus University Hospital
Collaborator
Zealand University Hospital
Collaborator
Herlev and Gentofte Hospital
Collaborator
Source ClinicalTrials.gov